|
|
Vaccine Detail
|
Viagenpumatucel-L Vaccine |
| Vaccine Information |
- Vaccine Name: Viagenpumatucel-L Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007088
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- HSP90B1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Cancer cell lines were used to express gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) (Fromm et al., 2016).
- Description: This is for Lung Cancer (NCT02439450). A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential antineoplastic activity. Upon administration of viagenpumatucel-L, the irradiated live tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs) into the blood stream, thereby activating antigen presenting cells, natural killer cells and priming potent cytotoxic T lymphocytes (CTLs) to respond against TAAs on the endogenous tumor cells. Furthermore, this vaccine may induce long-lived memory T cells that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL retention sequence of gp96, normally an endoplasmatic reticulum-resident chaperone peptide, with the Fc portion of mouse and human IgG1 (Fromm et al., 2016; NCIT_C61073).
|
| Host Response |
|
|
| References |
Fromm et al., 2016: Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination. Cancer immunology research. 2016; 4(9); 766-778. [PubMed: 27364122].
NCIT_C61073: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61073]
NCT02439450: [https://clinicaltrials.gov/ct2/show/NCT02439450]
|
|
